coronavirus
COVID-19: Commission authorizes third adapted vaccine for member states' autumn vaccination campaigns

The Commission has authorized the Nuvaxovid XBB.1.5-adapted COVID-19 vaccine, developed by Novavax. This is another important step in the fight against the disease. It is the first protein-based adapted vaccine authorized for this autumn and winter season.
The European Medicines Agency (EMA) carried out an in-depth evaluation of the vaccine. Following this evaluation, the Commission authorised the adapted vaccine under an expedited procedure so that member states have sufficient time to prepare for their autumn-winter vaccination campaigns.
In line with previous recommendations by the EMA and the European Centre for Disease Prevention and Control (ECDC), adults and adolescents from 12 years of age who require vaccination are invited to get a single dose, irrespective of their COVID-19 vaccination history.
Background
With the EU Vaccines Strategy, the Commission continues to ensure that member states have access to the latest authorised COVID-19 vaccines to protect the vulnerable members of their population and deal with the epidemiological evolution of the virus.
Novavax has adapted its COVID-19 vaccine to target the SARS-CoV-2 Omicron strain XBB.1.5. This is in line with ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 variants. The adapted vaccine is also expected to increase the breadth of immunity against current dominant and emerging variants.
More information
Safe COVID-19 vaccines for Europeans
Overview of the Commission's Response
Share this article:
-
South Sudan4 days ago
EU and international community, including media, urged to 'wake up' to 'genocide' in Sudan
-
Crime4 days ago
Commission welcomes political agreement on automated data exchange for police co-operation
-
Iran5 days ago
At the European Parliament, MEPs join Maryam Rajavi in urging EU to blacklist Iran regime’s Revolutionary Guards
-
Asylum policy4 days ago
EU received over 91,700 asylum applications in August 2023